龙津药业(002750) - 2018 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2018 was ¥82,849,713.12, representing a 39.41% increase compared to ¥59,428,956.12 in the same period last year[8] - Net profit attributable to shareholders decreased by 48.07% to ¥7,242,158.75 from ¥13,947,051.14 year-on-year[8] - The net profit after deducting non-recurring gains and losses fell by 59.68% to ¥4,462,584.37 compared to ¥11,068,594.97 in the previous year[8] - Basic and diluted earnings per share decreased by 47.99% to ¥0.0181 from ¥0.0348 year-on-year[8] - The weighted average return on equity was 1.12%, down from 2.06% in the previous year, reflecting a decrease of 0.94%[8] - The company expects net profit attributable to shareholders for the first half of 2018 to decline by 60.00% to 10.00%, ranging from ¥936.08 million to ¥2,106.18 million[21] Cash Flow - The net cash flow from operating activities increased significantly by 22,813.53% to ¥11,343,297.64, up from a negative cash flow of ¥49,940.70 in the same period last year[8] - Net cash flow from operating activities surged by 22,813.53% to ¥11,343,297.64, attributed to significant cash receipts from sales[16] - Investment activities generated a net cash flow of -¥37,882,326.00, primarily due to higher expenditures on financial products and fixed assets[16] Assets and Liabilities - Total assets at the end of the reporting period were ¥798,419,744.00, a 1.68% increase from ¥785,229,136.92 at the end of the previous year[8] - Net assets attributable to shareholders increased by 1.12% to ¥652,782,365.04 from ¥645,540,206.29 at the end of the previous year[8] - Cash and cash equivalents decreased by 37.44% to ¥44,347,629.05 due to higher expenditures on financial products than recoveries[15] - Other non-current assets increased by 669.96% to ¥16,120,620.00, due to prepayments for fixed and long-term assets[15] Expenses - Sales expenses rose by 127.04% to ¥61,243,851.66, reflecting increased marketing and promotional costs[15] - The company reported a 68.90% decrease in income tax expenses to ¥641,287.12, correlating with a reduction in total profit[15] Strategic Developments - The company is in the process of acquiring 100% equity of two subsidiaries, enhancing its market position[17] - The company anticipates increased sales costs due to expanded marketing efforts and higher R&D investments, impacting net profit[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,779[11] - The company received government subsidies amounting to ¥1,705,282.30 during the reporting period[9]